N.F.U. MUTUAL UNIT MANAGERS Ltd Purchases 10,240 Shares of Illumina, Inc. $ILMN

N.F.U. MUTUAL UNIT MANAGERS Ltd purchased a new stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 10,240 shares of the life sciences company’s stock, valued at approximately $2,802,000.

Other large investors have also recently bought and sold shares of the company. Gabelli Funds LLC raised its holdings in shares of Illumina by 2.0% in the third quarter. Gabelli Funds LLC now owns 5,100 shares of the life sciences company’s stock valued at $1,396,000 after buying an additional 100 shares during the last quarter. Meeder Advisory Services Inc. boosted its stake in shares of Illumina by 6.7% during the third quarter. Meeder Advisory Services Inc. now owns 2,987 shares of the life sciences company’s stock worth $817,000 after buying an additional 187 shares during the period. NWK Group Inc. purchased a new position in shares of Illumina during the third quarter worth about $7,202,000. Allianz SE purchased a new position in shares of Illumina during the third quarter worth about $249,000. Finally, Resona Asset Management Co. Ltd. grew its holdings in shares of Illumina by 3.2% during the third quarter. Resona Asset Management Co. Ltd. now owns 40,288 shares of the life sciences company’s stock worth $11,011,000 after buying an additional 1,267 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina News Roundup

These are some of the ILMN news items that stood out recently:

  • Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result highlights the company’s data and AI capabilities, although the financial impact is not yet clear. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
  • Positive Sentiment: A proposed Senate bill would clarify Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support demand for sequencing, but the proposal remains early-stage. Genomic Answers for Children’s Health Act of 2026
  • Negative Sentiment: Voluntary Class II recalls linked to cybersecurity vulnerabilities in several diagnostic sequencing instruments have heightened concerns about operational risk and data integrity. The report also notes recent weakness in the shares, adding to near-term pressure. Is Illumina Undervalued Following Its Cybersecurity Recalls?

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $192.82 on Friday. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company has a 50-day moving average price of $248.27 and a 200 day moving average price of $181.05. The company has a market cap of $29.15 billion, a P/E ratio of 33.19, a PEG ratio of 2.62 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the firm posted $1.34 EPS. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Research analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ILMN shares. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $135.00 to $260.00 in a research report on Wednesday, September 9th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Royal Bank Of Canada upped their price target on Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Deutsche Bank downgraded Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, TD Cowen lifted their price objective on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Nine equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $243.72.

View Our Latest Stock Analysis on Illumina

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 98,833 shares of the company’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the transaction, the director owned 208,826 shares of the company’s stock, valued at $45,288,094.62. This represents a 32.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Scott D. Ericksen sold 267 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the transaction, the chief accounting officer owned 14,029 shares of the company’s stock, valued at $3,054,955.04. The trade was a 1.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,201,292 shares of company stock valued at $270,151,290 over the last three months. Insiders own 2.90% of the company’s stock.

Illumina Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.